Kensei Yamaguchi
Overview
Explore the profile of Kensei Yamaguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
274
Citations
6618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moehler M, Oh D, Kato K, Arkenau T, Tabernero J, Lee K, et al.
Adv Ther
. 2025 Mar;
PMID: 40075025
Introduction: Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo plus ICC in RATIONALE-305 in patients with locally advanced unresectable or metastatic human...
2.
Shitara K, Janjigian Y, Ajani J, Moehler M, Yao J, Wang X, et al.
Nat Med
. 2025 Mar;
PMID: 40055521
First-line nivolumab-plus-chemotherapy demonstrated superior overall survival (OS) and progression-free survival versus chemotherapy for advanced gastroesophageal adenocarcinoma with programmed death ligand 1 combined positive score ≥ 5, meeting both primary end...
3.
Udagawa S, Osumi H, Ooki A, Shimozaki K, Wakatsuki T, Fukuoka S, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 40014187
Background: Early tumor shrinkage (ETS) and depth of response (DpR) are early indicators of survival in patients with metastatic colorectal cancer (mCRC) undergoing anti-epidermal growth factor receptor monoclonal antibody treatment....
4.
Shimozaki K, Ooki A, Yoshino K, Tamba M, Udagawa S, Osumi H, et al.
Ther Adv Med Oncol
. 2025 Feb;
17:17588359251322670.
PMID: 40012706
Background: Although the emergence of immunotherapy has benefited patients with advanced gastric cancer (AGC), the magnitude of the benefit among real-world patients with HER2-negative AGC remains unclear. Objectives: The current...
5.
Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, et al.
Nat Cancer
. 2025 Feb;
PMID: 39972105
Platinum-based definitive chemoradiotherapy (dCRT) is the standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) that invades the aorta, vertebral body or trachea; however, complete response...
6.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al.
Nat Commun
. 2025 Jan;
16(1):704.
PMID: 39814812
No abstract available.
7.
Terayama M, Ohashi M, Yamaguchi K, Takahari D, Makuuchi R, Hayami M, et al.
Ann Gastroenterol Surg
. 2025 Jan;
9(1):60-68.
PMID: 39759998
Background: The standard adjuvant chemotherapy regimen for stage III gastric cancer is docetaxel plus S-1 (DS) based on the results of the START-II trials. However, in clinical practice some patients...
8.
Tamba M, Okamura A, Osumi H, Imamura Y, Kanamori J, Ogura M, et al.
Esophagus
. 2025 Jan;
PMID: 39755858
Background And Purpose: It remains unclear whether the lymph-node ratio (LNR) is a relevant factor for the risk of recurrence following neoadjuvant chemotherapy (nCT) with docetaxel, cisplatin, and 5-fluorouracil (DCF),...
9.
Hatori M, Fukuoka S, Kimura S, Kawakami K, Yamaguchi K, Yamaguchi M
Oncology
. 2024 Dec;
1-9.
PMID: 39647476
Introduction: Cisplatin-based highly emetogenic chemotherapy is recommended in combination with neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3-receptor antagonist (5HT3RA), dexamethasone (DEX), and olanzapine. However, olanzapine is contraindicated in patients with preexisting diabetes mellitus...
10.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al.
Nat Commun
. 2024 Nov;
15(1):10213.
PMID: 39587050
DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic...